Interventional Glaucoma

Joel S. Schuman, MD, FACS, highlights home tonometry, virtual visual fields, and portable OCT devices as promising tools, while noting concerns around data reliability, patient adherence, and reimbursement.

From artificial intelligence to home monitoring, Joel Schuman, MD, of Wills Eye Hospital, explores the innovations that could change how clinicians detect and treat glaucoma in the new year.

NCX 470 is Nicox’s lead dual-mechanism bimatoprost eye drop for lowering IOP in open-angle glaucoma or ocular hypertension.

The study evaluated thermal dynamics associated with CW-TSCPC and TLT using MicroPulse technology, such as temperature peak, exposure duration, and thermal spread in a simulated ciliary body using computer modeling.

The trial is evaluating the company’s femtosecond laser trabeculotomy procedure in comparison to selective laser trabeculoplasty

The SAPPHIRE trial evaluating the VisiPlate is currently underway across several sites across the US, with more site activations scheduled for 2026

The BIM-IOL System is for the treatment of elevated IOP in patients with mild-to-moderate open-angle glaucoma (OAG) or ocular hypertension (OHT).

Ophthalmologists discuss how advanced imaging, MIGS, and home monitoring are reshaping decision-making in complex glaucoma cases.

Surgeons reflect on milestones that have redefined patient care—and share a glimpse of the advances that promise to shape the next era of eye health.

The VITA Trial is a prospective pilot study on the VisiPlate Aqueous Shunt in patients with with open-angle glaucoma.

From MIGS integration to remote monitoring and next-generation therapeutics, glaucoma specialists explore how new approaches are redefining patient outcomes.

The 24-month results of this first-in-human trial supports the potential long-term outcomes of this system to lower IOP.

Earlier use of SLT, sustained-release drug delivery, and MIGS is reframing glaucoma care.

Roundtable discussion explores surgical and sustained-release options.

In this murine model of glaucoma, SPG302 was administered daily to 3-month-old mice for 8 weeks.

Explore groundbreaking advancements in eye care from the 2000s, including LASIK innovations, anti-VEGF treatments, and enhanced imaging technologies.

The VisiPlate aqueous shunt is made of a patented metamaterial that has been designed to be non-fibrotic and is many times thinner than a human hair, according to the company.

Explore the groundbreaking advancements in ophthalmic technology from the 1980s and 1990s, including excimer lasers, LASIK, and innovative imaging techniques.

From lasers to lenses, the 1970s redefined vision care through breakthroughs in surgery, imaging, and therapeutics.

Lupin notes that the acquisition will help to strengthen the company by “integrating VISUfarma’s established commercial operations.”

Bimatoprost ophthalmic solution 0.01% is a prostaglandin analog for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension and is the generic equivalent of LUMIGAN.

Potential loss to follow-up is a critical issue for these patients with glaucoma.